

SUPPLEMENTARY TABLES

Supplementary Table 1. Patient information.

Case n=24	Gender	Age	Cancer form	TNM stage
1	M	73	Undifferentiated cancer	T4N2M0
2	M	60	Undifferentiated cancer	T4N3M0
3	F	62	Undifferentiated cancer	T2N1M0
4	M	43	Undifferentiated cancer	T2N2M0
5	F	71	Non-keratinizing differentiated cancer	T2N1M0
6	M	70	Undifferentiated cancer	T3N1M0
7	M	61	Undifferentiated cancer	T3N1M0
8	M	28	Undifferentiated cancer	T3N3M0
9	F	55	Undifferentiated cancer	T2N1M0
10	M	61	Undifferentiated cancer	T3N3M0
11	M	43	Undifferentiated cancer	T2N1M0
12	F	52	Undifferentiated cancer	T2N0M0
13	F	54	Undifferentiated cancer	T3N3M0
14	M	47	Undifferentiated cancer	T3N2M0
15	M	77	Undifferentiated cancer	T4N1M0
16	M	27	Undifferentiated cancer	T4N2M0
17	M	60	Non-keratinizing differentiated cancer	T4N1M0
18	F	56	Undifferentiated cancer	T3N0M0
19	M	59	Non-keratinizing differentiated cancer	T4N1M1
20	M	35	Undifferentiated cancer	T2N3M0
21	M	54	Undifferentiated cancer	T2N0M0
22	M	30	Undifferentiated cancer	T4N1M0
23	M	50	Non-keratinizing differentiated cancer	T3N1M0
24	M	54	Undifferentiated cancer	T3N0M0

Supplementary Table 2. Quantitative real-time PCR primers.

miRNA	Primer	Sequence
EBV-miR-BART13-3p	miRNA	UGUAAUUGCCAGGGACGGCUGA
	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATT
	Forward primer	CGCACTGGATACGACTCAGCC
	Reversed primer	GGGACGTGTAACCTGCCAGG
U6	RT	CAGTGCAGGGTCCGAGGTAT
	Forward primer	CGAATTTGCGTGTGCATCCT
	Reversed primer	CTCGCTTCGGCAGCACATA
	Forward primer	CGAATTTGCGTGTGCATCCT
mRNA	Primer	Sequence
	ABI2	Forward primer
c-JUN	Reversed primer	AGGTTGGCTGGAGCAATAATC
	Forward primer	TCCAAGTGCCGAAAAAGGAAG
SNAIL	Reversed primer	CGAGTTCTGAGCTTTCAAGGT
	Forward primer	TAATCCAGAGTTTACCTTCCAGC

SLUG	Reversed primer	CTCATCTGACAGGGAGGTCAG
	Forward primer	CCCTGAAGATGCATATTCGGA
CTNNB1	Reversed primer	CTGCAAATGCTCTGTTCAG
	Forward primer	TGCTGAAGGTGCTATCTGTCTG
ZEB1	Reversed primer	CCTTCCATCCCTTCCTGTTT
	Forward primer	TCACTAGTGTTTACCAGAACAGTG
ZEB2	Reversed primer	GAACACTGTTCTGGTCAGCA
	Forward primer	CTACAAGCGCTTGACATCAC
TWIST1	Reversed primer	TAGCATTGGGTGCTGATCTGTC
	Forward primer	AGTCTTACGAGGAGCTGCAG
FOXC2	Reversed primer	CTCTGGAGGACCTGGTAGAG
	Forward primer	CTTCTACCGGGAGAACAAGC
GAPDH	Reversed primer	CTCCTTCTCCTTGGACACGT
	Forward primer	GAGTCAACGGATTTGGTCGT
	Reversed primer	GACAAGCTTCCCCTTCTCAG

Supplementary Table 3. Antibodies used for the study.

Antibody	Company	Catalog no.	Dilution ratio
Western blotting			
GAPDH	Servicebio	GB11002	1:2000
E-cadherin	CST	9782T	1:1000
Vimentin	CST	9782T	1:1000
ABI2	Proteintech	14890-1-AP	1:1000
c-JUN	Abclonal	A11378	1:1000
SLUG	CST	9782T	1:1000
Rabbit	Servicebio	GB23303	1:3000
Immunohistochemistry			
E-cadherin	CST	9782T	1:400
Vimentin	CST	9782T	1:200
ABI2	Proteintech	14890-1-AP	1:200
Pan-Keratin	Proteintech	26411-1-AP	1:2000
Immunofluorescence			
E-cadherin	CST	9782T	1:200
Vimentin	CST	9782T	1:100
ABI2	Proteintech	14890-1-AP	1:100
c-JUN	Abclonal	A11378	1:100
SLUG	CST	9782T	1:400